Keywords
Pediatric patients
Proton pump inhibitor
Corticosteroids
Dupilumab
Diet
How to Cite
Abstract
Background: The treatment of eosinophilic esophagitis (EoE) is based on diets or drugs, with either being the first choice. Proton pump inhibitor (PPI) or swallowed topical corticosteroids (STC) are classically used, and more recently the use of dupilumab has been described as a therapeutic option.
Case report: A pediatric patient with difficult-to-manage eosinophilic esophagitis, diagnosed before the age of 2 years, in which the simultaneous use of triple pharmacological therapy (Dupilumab, PPI and STC) has been necessary for the histological control of the disease.
Conclusions: It is a case of interest since in current guidelines the use of combined pharmacological therapies is not recommended or fully described. In addition, it is a case in which a good response to treatment with dupilumab is observed despite not meeting the indication criteria of the pharmacological label, in terms of age and weight.
Keywords: Eosinophilic esophagitis; Pediatric patients; Proton pump inhibitor; Corticosteroids; Dupilumab; Diet.
References
1. Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J 2017; 5 (3): 335-358. doi: 10.1177/2050640616689525
2. Dhar A, Haboubi HN, Attwood SE, et al. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut 2022; 71 (8): 1459-1487. doi: 10.1136/gutjnl-2022-327326
3. Votto M, De Filippo M, Caimmi S, et al. A Practical Update on Pediatric Eosinophilic Esophagitis. Children (Basel) 2023; 10 (10): 1620. doi: 10.3390/children10101620
4. Arias A, González-Cervera J, Tenias JM, Lucendo AJ. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology 2014; 146 (7): 1639-1648. doi: 10.1053/j.gastro.2014.02.006
5. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology 2020; 158 (6): 1776-1786. doi: 10.1053/j.gastro.2020.02.038
6. Hirano I, Furuta GT. Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis. Gastroenterology 2020; 158 (4): 840-851. doi: 10.1053/j.gastro.2019.09.052
7. Al-Horani RA, Chiles R. First Therapeutic Approval for Eosinophilic Esophagitis. Gastroenterol Insights. 2022; 13 (3): 238-244. doi: 10.3390/gastroent13030024
8. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med 2022; 387 (25): 2317-2330. doi: 10.1056/NEJMoa2205982
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Revista Alergia México